Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.

[1]  I. Wistuba,et al.  Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial , 2021, Clinical and translational medicine.

[2]  E. Felip,et al.  Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients , 2021, Cancers.

[3]  Jae Cheol Lee,et al.  Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study , 2021, Translational lung cancer research.

[4]  L. Guerra,et al.  Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience , 2021, Cancers.

[5]  B. Neyns,et al.  The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. , 2021, Clinical lung cancer.

[6]  N. Ajami,et al.  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial , 2021, Nature Medicine.

[7]  M. Szczyrek,et al.  Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients , 2021, Frontiers in Oncology.

[8]  C. Porta,et al.  A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC , 2020, Cancer Immunology, Immunotherapy.

[9]  A. Tsung,et al.  Surgical Stress Promotes Tumor Progression: A Focus on the Impact of the Immune Response , 2020, Journal of clinical medicine.

[10]  T. Mok,et al.  Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study , 2020, International journal of cancer.

[11]  C. Paweletz,et al.  Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC , 2020, Journal for ImmunoTherapy of Cancer.

[12]  W. Hwang,et al.  Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma , 2020, Journal for ImmunoTherapy of Cancer.

[13]  D. Neuberg,et al.  A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma , 2020, Nature Medicine.

[14]  M. Tiseo,et al.  Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. , 2020, Lung cancer.

[15]  Jing Wang,et al.  Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. , 2020, Lung cancer.

[16]  Yi-long Wu,et al.  Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study , 2020, Journal for immunotherapy of cancer.

[17]  S. Novello,et al.  18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival , 2020, Cancers.

[18]  G. Broeckx,et al.  Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients , 2020, Cancers.

[19]  O. Zmora,et al.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period , 2020, Nature Reviews Clinical Oncology.

[20]  S. H. van der Burg,et al.  Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients , 2020, Cancer Immunology, Immunotherapy.

[21]  Xiawei Wei,et al.  Surgical trauma‐induced immunosuppression in cancer: Recent advances and the potential therapies , 2020, Clinical and translational medicine.

[22]  Yueping Jin,et al.  The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Ying Cheng,et al.  Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  S. Moffatt-Bruce,et al.  Hospital cost and clinical effectiveness of robotic‐assisted versus video‐assisted thoracoscopic and open lobectomy: A propensity score–weighted comparison , 2019, The Journal of thoracic and cardiovascular surgery.

[25]  P. Laurent-Puig,et al.  Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. , 2019, Journal of thoracic disease.

[26]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[27]  L. Tai,et al.  Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity , 2018, Journal of Immunotherapy for Cancer.

[28]  J. Roth,et al.  Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. , 2018, The Annals of thoracic surgery.

[29]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[30]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[31]  J. Zhao,et al.  Elevated peripheral blood B lymphocytes and CD3+CD4−CD8− T lymphocytes in patients with non-small cell lung cancer: A preliminary study on peripheral immune profile , 2018, Oncology letters.

[32]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[33]  Eran Sharon,et al.  Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial , 2017, Clinical Cancer Research.

[34]  Kaitlin M. Woo,et al.  Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy , 2017, Annals of surgery.

[35]  L. Sequist,et al.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.

[36]  Y. Shaked.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects , 2016, Nature Reviews Clinical Oncology.

[37]  Zhirong Sun,et al.  Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway , 2015, Cancer Immunology, Immunotherapy.

[38]  D. Boffa,et al.  Hospital readmission after pulmonary lobectomy is not affected by surgical approach. , 2015, The Annals of thoracic surgery.

[39]  T. Miyasho,et al.  Factors Affecting Cytokine Change After Esophagectomy for Esophageal Cancer , 2015, Annals of Surgical Oncology.

[40]  M. Cuesta,et al.  Surgical Stress Response and Postoperative Immune Function After Laparoscopy or Open Surgery With Fast Track or Standard Perioperative Care: A Randomized Trial , 2012, Annals of surgery.

[41]  S. Ben-Eliyahu,et al.  Improving Postoperative Immune Status and Resistance to Cancer Metastasis: A Combined Perioperative Approach of Immunostimulation and Prevention of Excessive Surgical Stress Responses , 2011, Annals of surgery.

[42]  K. Horgan,et al.  Surgery induced immunosuppression. , 2011, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[43]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[45]  M. Cuesta,et al.  Immunological Changes After Minimally Invasive or Conventional Esophageal Resection for Cancer: A Randomized Trial , 2013, World Journal of Surgery.

[46]  L. Nespoli,et al.  Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C. , 2006, Anticancer research.

[47]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .